Virtu Financial LLC Buys New Shares in Moleculin Biotech, Inc. (NASDAQ:MBRX)

Virtu Financial LLC bought a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 25,302 shares of the company’s stock, valued at approximately $93,000. Virtu Financial LLC owned about 0.09% of Moleculin Biotech at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new position in Moleculin Biotech in the first quarter valued at $56,000. Geode Capital Management LLC increased its stake in Moleculin Biotech by 35.9% in the second quarter. Geode Capital Management LLC now owns 237,586 shares of the company’s stock valued at $871,000 after purchasing an additional 62,764 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Moleculin Biotech during the second quarter worth about $114,000. Cubist Systematic Strategies LLC acquired a new stake in Moleculin Biotech during the first quarter worth about $109,000. Finally, Squarepoint Ops LLC increased its stake in Moleculin Biotech by 134.2% during the first quarter. Squarepoint Ops LLC now owns 28,904 shares of the company’s stock worth $118,000 after acquiring an additional 16,562 shares during the last quarter. Hedge funds and other institutional investors own 10.37% of the company’s stock.

Shares of NASDAQ:MBRX opened at $2.20 on Thursday. The business has a 50-day moving average of $2.66 and a two-hundred day moving average of $3.12. Moleculin Biotech, Inc. has a 12 month low of $1.98 and a 12 month high of $8.78.

Moleculin Biotech (NASDAQ:MBRX) last issued its earnings results on Thursday, November 11th. The company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. Research analysts predict that Moleculin Biotech, Inc. will post -0.71 EPS for the current fiscal year.

Separately, Zacks Investment Research lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, November 17th.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML); and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML.

Featured Story: Stock Symbols and CUSIP Explained

Want to see what other hedge funds are holding MBRX? Visit to get the latest 13F filings and insider trades for Moleculin Biotech, Inc. (NASDAQ:MBRX).

Institutional Ownership by Quarter for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with's FREE daily email newsletter.